Expert Interview
Taking a look at the treatment landscape for treating patients with obesity without Type 2 Diabetes and the non advancement of the twice-daily dosing of oral GLP-1 agonist, Danuglipron, into Phase 3 studies.
Ticker(s): PFEInstitution: City of Hope National Medical center
- Assistant professor in Endocrinology at City of Hope national Medical center
- Currently manages 100 patients with Obesity without type 2 diabetes
- Not familiar with danuglipron but has been using Rybelsus, oral GLp-1 agonist for weight loss
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
